PEMBROLIZUMAB (KEYTRUDA) Is Now Indicated For Recurrent or Metastatic HNSCC

• September 16, 2016
• Clinical Practice Updates, Drugs

FDA granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp.) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Click here for Merck’s announcement

• For More FDA Information Click Here

• Medication Guide

• Prescribing Information

Please Note: DOSAGE AND ADMINISTRATION

• HNSCC: 200 mg every 3 weeks.
• Melanoma and NSCLC: 2 mg/kg every 3 weeks.